# GLAUKOS Corp

Summary updated: 2026-10-02T14:07:05.60257Z
Canonical: https://finbar.com/research/companies/glaukos-corp

## Overview

Glaukos is an ophthalmic medical technology and pharmaceutical company developing and commercializing treatments for glaucoma, corneal disorders, and retinal diseases. Its portfolio includes minimally invasive glaucoma surgery devices such as the iStent family, the sustained-release iDose TR implant, and corneal-health products including Photrexa and Epioxa. The company describes its mission as transforming vision through novel, dropless platforms. [1](https://app.finbar.com/go?id=P144456992)[2](https://www.glaukos.com/about-us/)

Headquartered in Aliso Viejo, California, Glaukos has U.S. manufacturing and research operations and international subsidiaries in Australia, Brazil, Canada, Germany, Japan, and the U.K. [3](https://app.finbar.com/go?id=P108106377)[4](https://app.finbar.com/go?id=P31387439) The company reported more than 1,000 employees worldwide in its 2025 sustainability report. [5](https://www.glaukos.com/wp-content/uploads/2026/04/Glaukos_Corp-SustainabilityReport2025.pdf) Net sales were $507.4 million for full-year 2025 and $336.2 million for the first half of 2026. [6](https://app.finbar.com/go?id=P9036450)[7](https://app.finbar.com/go?id=T16530688)
[1](https://app.finbar.com/go?id=P144456992)[2](https://www.glaukos.com/about-us/)[3](https://app.finbar.com/go?id=P108106377)[4](https://app.finbar.com/go?id=P31387439)[5](https://www.glaukos.com/wp-content/uploads/2026/04/Glaukos_Corp-SustainabilityReport2025.pdf)[6](https://app.finbar.com/go?id=P9036450)[7](https://app.finbar.com/go?id=T16530688)[2](https://www.glaukos.com/about-us/)[5](https://www.glaukos.com/wp-content/uploads/2026/04/Glaukos_Corp-SustainabilityReport2025.pdf)

## Products & services

Glaukos’s glaucoma products include the iStent family of trabecular micro-bypass devices. The iStent inject W is a preloaded system that delivers two stents through one corneal entry during cataract surgery; iStent infinite is supplied with three preloaded stents and can place them across up to approximately six clock hours of Schlemm’s canal. iStent infinite is indicated for certain patients with glaucoma uncontrolled by prior medical and surgical therapy, and may be used alone or with cataract surgery. [8](https://app.finbar.com/go?id=P26211856)[9](https://app.finbar.com/go?id=P3827808) iDose TR is an intracameral sustained-release travoprost implant for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension; the current product information specifies a 75-mcg implant. [10](https://app.finbar.com/go?id=P41701457)[11](https://www.glaukos.com/glaucoma/products/idose-tr/)

For corneal health, Photrexa Viscous and Photrexa are used with the KXL ultraviolet-A light system for epithelium-off corneal cross-linking to treat progressive keratoconus and corneal ectasia following refractive surgery. [12](https://app.finbar.com/go?id=P115358877)[13](https://www.glaukos.com/prescribing-information/photrexa-viscous-and-photrexa/) Epioxa is an epithelium-on, incision-free treatment for keratoconus, used with the O₂n System and Boost Goggles; its prescribing information specifies EPIOXA HD 0.239% and EPIOXA 0.177% for adults and patients aged 13 and older. [14](https://app.finbar.com/go?id=P8522579)[15](https://app.finbar.com/go?id=P144456998)[16](https://www.glaukos.com/wp-content/uploads/2026/02/epioxa-prescribing-information.pdf) Glaukos also describes a one-year product warranty in general, with an extended-warranty option for KXL systems. [17](https://app.finbar.com/go?id=P121645524)

For FY2025, glaucoma products accounted for $421.070 million, approximately 83%, of net sales, while corneal-health products accounted for $86.372 million, approximately 17%. These are category-level shares; the reported figures do not give separate sales percentages for individual products. [18](https://app.finbar.com/go?id=T2344044)
[8](https://app.finbar.com/go?id=P26211856)[9](https://app.finbar.com/go?id=P3827808)[10](https://app.finbar.com/go?id=P41701457)[12](https://app.finbar.com/go?id=P115358877)[14](https://app.finbar.com/go?id=P8522579)[15](https://app.finbar.com/go?id=P144456998)[17](https://app.finbar.com/go?id=P121645524)[18](https://app.finbar.com/go?id=T2344044)[18](https://app.finbar.com/go?id=T2344044)[11](https://www.glaukos.com/glaucoma/products/idose-tr/)[13](https://www.glaukos.com/prescribing-information/photrexa-viscous-and-photrexa/)[16](https://www.glaukos.com/wp-content/uploads/2026/02/epioxa-prescribing-information.pdf)

## Geographic presence

Glaukos is headquartered in Aliso Viejo, California, where it has administrative, laboratory, research and development, and warehouse facilities. Its manufacturing sites include San Clemente, California, and Burlington, Massachusetts. The company also reported breaking ground in September 2025 on a planned research, development and manufacturing facility in Huntsville, Alabama. Photrexa and associated drug formulations are manufactured by third parties in the United States and Germany. [3](https://app.finbar.com/go?id=P108106377)[19](https://app.finbar.com/go?id=P70116320)[20](https://investors.glaukos.com/news/news-details/2025/Glaukos-%20Breaks-Ground-on-New-Research-Development-and-Manufacturing-Facility-in-Huntsville-Alabama/default.aspx)

Glaukos reports revenue geographically as United States and international, rather than by individual country. In 2025, U.S. revenue was $375.0 million (73.9% of total) and international revenue was $132.4 million (26.1%). [18](https://app.finbar.com/go?id=T2344044)[18](https://app.finbar.com/go?id=T2344044)[18](https://app.finbar.com/go?id=T2344044) In the first half of 2026, U.S. revenue was $259.1 million (77.1%) and international revenue was $77.1 million (22.9%). [21](https://app.finbar.com/go?id=T16530706)[21](https://app.finbar.com/go?id=T16530706)[21](https://app.finbar.com/go?id=T16530706) International subsidiaries lease facilities in Australia, Brazil, Canada, Germany, Japan and the United Kingdom; international sales are primarily through these subsidiaries, supplemented by independent distributors in some markets. [3](https://app.finbar.com/go?id=P108106377)[22](https://app.finbar.com/go?id=P84862109)
[3](https://app.finbar.com/go?id=P108106377)[19](https://app.finbar.com/go?id=P70116320)[20](https://investors.glaukos.com/news/news-details/2025/Glaukos-%20Breaks-Ground-on-New-Research-Development-and-Manufacturing-Facility-in-Huntsville-Alabama/default.aspx)[18](https://app.finbar.com/go?id=T2344044)[18](https://app.finbar.com/go?id=T2344044)[18](https://app.finbar.com/go?id=T2344044)[21](https://app.finbar.com/go?id=T16530706)[21](https://app.finbar.com/go?id=T16530706)[21](https://app.finbar.com/go?id=T16530706)[22](https://app.finbar.com/go?id=P84862109)[20](https://investors.glaukos.com/news/news-details/2025/Glaukos-%20Breaks-Ground-on-New-Research-Development-and-Manufacturing-Facility-in-Huntsville-Alabama/default.aspx)

## Business segments

Glaukos reports one operating and reportable segment: the development and commercialization of ophthalmic therapies for glaucoma, corneal disorders, and retinal diseases. The company’s CEO reviews consolidated results to allocate resources and evaluate performance. Accordingly, the company does not report revenue contributions across multiple segments; its sole reported segment encompasses the consolidated business. [23](https://app.finbar.com/go?id=P144457150)[24](https://app.finbar.com/go?id=P144457187)

For additional context, FY2025 revenue was disaggregated by product category—not by segment—as $421.1 million from Glaucoma (approximately 83%) and $86.4 million from Corneal Health (approximately 17%). These product-category percentages should not be interpreted as segment contributions. [18](https://app.finbar.com/go?id=T2344044)
[23](https://app.finbar.com/go?id=P144457150)[24](https://app.finbar.com/go?id=P144457187)[18](https://app.finbar.com/go?id=T2344044)

## Company history

Glaukos was incorporated in Delaware in 1998. Its company history traces the development of its trabecular micro-bypass stent to 1999 and its first human implant to 2001; the company attributes the original concept to glaucoma specialist Dr. Richard “Rick” Hill. [25](https://app.finbar.com/go?id=P68647423)[26](https://www.glaukos.com/about-us/our-history/)

In 2012, Glaukos launched iStent in the United States after FDA clearance, marking its entry into the market for micro-invasive glaucoma surgery. It completed its initial public offering in 2015, then expanded into corneal cross-linking with FDA approval of Photrexa in 2016. FDA approved iStent inject W in 2018, and Glaukos completed its acquisition of corneal cross-linking company Avedro in 2019. [8](https://app.finbar.com/go?id=P26211856)[27](https://www.sec.gov/Archives/edgar/data/1192448/000155837020001628/ex-99d1.htm)[28](https://investors.glaukos.com/news/news-details/2015/Glaukos-Corporation-Announces-Closing-of-Its-Initial-Public-Offering/default.aspx)[29](https://app.finbar.com/go?id=P144457158)[30](https://investors.glaukos.com/news/news-details/2019/Glaukos-Completes-Acquisition-of-Avedro-Inc/default.aspx)

Subsequent milestones included FDA clearance of iStent infinite in 2022 and approval of the sustained-release glaucoma implant iDose TR in 2023, followed by its controlled U.S. launch in 2024. In 2025, Glaukos acquired Mobius Therapeutics and received FDA approval for Epioxa for keratoconus; the company reported beginning a controlled commercial launch of Epioxa in early 2026. [9](https://app.finbar.com/go?id=P3827808)[31](https://app.finbar.com/go?id=P29838816)[32](https://app.finbar.com/go?id=P105622452)[33](https://app.finbar.com/go?id=P121969613)[29](https://app.finbar.com/go?id=P144457158)
[25](https://app.finbar.com/go?id=P68647423)[26](https://www.glaukos.com/about-us/our-history/)[8](https://app.finbar.com/go?id=P26211856)[27](https://www.sec.gov/Archives/edgar/data/1192448/000155837020001628/ex-99d1.htm)[28](https://investors.glaukos.com/news/news-details/2015/Glaukos-Corporation-Announces-Closing-of-Its-Initial-Public-Offering/default.aspx)[29](https://app.finbar.com/go?id=P144457158)[30](https://investors.glaukos.com/news/news-details/2019/Glaukos-Completes-Acquisition-of-Avedro-Inc/default.aspx)[9](https://app.finbar.com/go?id=P3827808)[31](https://app.finbar.com/go?id=P29838816)[32](https://app.finbar.com/go?id=P105622452)[33](https://app.finbar.com/go?id=P121969613)[26](https://www.glaukos.com/about-us/our-history/)[27](https://www.sec.gov/Archives/edgar/data/1192448/000155837020001628/ex-99d1.htm)[28](https://investors.glaukos.com/news/news-details/2015/Glaukos-Corporation-Announces-Closing-of-Its-Initial-Public-Offering/default.aspx)[30](https://investors.glaukos.com/news/news-details/2019/Glaukos-Completes-Acquisition-of-Avedro-Inc/default.aspx)

## Sources

1. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144456992)
2. [www.glaukos.com](https://www.glaukos.com/about-us/)
3. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P108106377)
4. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P31387439)
5. [www.glaukos.com](https://www.glaukos.com/wp-content/uploads/2026/04/Glaukos_Corp-SustainabilityReport2025.pdf)
6. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P9036450)
7. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16530688)
8. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P26211856)
9. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P3827808)
10. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P41701457)
11. [www.glaukos.com](https://www.glaukos.com/glaucoma/products/idose-tr/)
12. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P115358877)
13. [www.glaukos.com](https://www.glaukos.com/prescribing-information/photrexa-viscous-and-photrexa/)
14. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P8522579)
15. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144456998)
16. [www.glaukos.com](https://www.glaukos.com/wp-content/uploads/2026/02/epioxa-prescribing-information.pdf)
17. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121645524)
18. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=T2344044)
19. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P70116320)
20. [investors.glaukos.com](https://investors.glaukos.com/news/news-details/2025/Glaukos-%20Breaks-Ground-on-New-Research-Development-and-Manufacturing-Facility-in-Huntsville-Alabama/default.aspx)
21. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16530706)
22. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P84862109)
23. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144457150)
24. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144457187)
25. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P68647423)
26. [www.glaukos.com](https://www.glaukos.com/about-us/our-history/)
27. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1192448/000155837020001628/ex-99d1.htm)
28. [investors.glaukos.com](https://investors.glaukos.com/news/news-details/2015/Glaukos-Corporation-Announces-Closing-of-Its-Initial-Public-Offering/default.aspx)
29. [GLAUKOS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144457158)
30. [investors.glaukos.com](https://investors.glaukos.com/news/news-details/2019/Glaukos-Completes-Acquisition-of-Avedro-Inc/default.aspx)
31. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29838816)
32. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P105622452)
33. [GLAUKOS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121969613)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.